$\hat{\varphi}^{\mathbf{t}_{i}}$

INTERNATIONAL SEARCH REPORT

Fax:0117932930

tional Application No

				/GB2004	/002351
CLASSIFICATION OF SUBJECT & PC 7 CO7K16/08 A61P31/00	CO7K16/12	C07K16/14	C07K16/16	C07K1	6/18
ccording to International Patent Class	ification (IPC) or to bo	th national classification :	and IPC		
FIELDS SEARCHED inimum documentation searched (da	nonitication system fall	lower by risselfication sy	nbols)		
PC 7 CO7K	Bancandi System top		,		
ocumentation searched other than m	inimum documentation	i to the extent that such d	ocuments are include	in the fields sea	rched
lectronic data base consulted during to PO-Internal, BIOSIS	•		d, where practical, so	earch lerms used)	
. DOCUMENTS CONSIDERED TO E					Relevant to daim No.
ategory * Citation of document, with	In indication, where a	ppropriate, of the relevant	passages		Melevara to Claim Ma
botulinum i REVIEWS IN vol. 12, no pages 29-37	MAYER-CN ET AL.: "Antitoxin therapy for botulinum intoxication" REVIEWS IN MEDICAL MICROBIOLOGY, vol. 12, no. 1, January 2001 (2001-01), pages 29-37, XP002299273 the whole document				
soluble mou rabies viru JOURNAL OF	Jse scFv fra Js." VIROLOGICAL D. 2, Septem 233, XPOO229	nage-displayed agments neutra METHODS. SEP aber 1997 (199 19274	1997, 7-09),		1-21
Y Further documents are listed	in the confinuation of	box C.	Patent family m	sembers are listed	in suinėx.
"A" document defining the general sonsidered to be of particular relation grate "E" earlier document but published filling date "L" document which may throw dound which is cited to establish the citation or other special reason other means "O" document reterring to an oral document reterring to an oral document published prior to the later than the priority date class	ents: State of the art which is elevance on or after the international filing damed.	is not Ettonal 'X' S) or Other You	ched to understand invention document of particular involve an invention document of particular document of particular cannot be considered.	the principle or the principle or the principle or the principle or the red novel or cannot be step when the desired to involve an inclined with one or mainstion being obviced the same paten	claimed invention to be considered to be considered to be considered to be considered to be claimed invention of the step when the lone other such document to a person skilled tamily
Date of the actual completion of the			21/10/2		
7 October 200	<u> </u>	•	Authorized officer		
- I	Mice, P.B. 5818 Parel	<u> </u>	Lechner	0	

#1 *****

():

INTERNATIONAL SEARCH REPORT

tilonal Application No. /GB2004/002351 C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Charlon of document, with indication, where appropriate, of the relevant passages Relevant to claim No. STEELE E J ET AL: "Further evidence for 1-21 cross-linking as a protective factor in experimental cholera: properties of antibody fragments." THE JOURNAL OF INFECTIOUS DISEASES. AUG 1975, vol. 132, no. 2, August 1975 (1975-08), pages 175-180, XP009037451 ISSN: 0022-1899 abstract ISMAIL M ET AL: "Pharmacokinetics of 1-21 A 125I-labelled IgG, F(ab')2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use." TOXICON: OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXINOLOGY. NOV 1998, vol. 36, no. 11, November 1998 (1998-11), pages 1523-1528, XP002299275 ISSN: 0041-0101 the whole document BEHR T M ET AL: "Anti-carcinoembryonic 1-21 antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?" CANCER. 15 DEC 1997, vol. 80, no. 12 Suppl, 15 December 1997 (1997-12-15), pages 2436-2457, XP002299276 ISSN: 0008-543X the whole document P,A MAYERS CARL N ET AL: "Anti-immunoglobulin 1-21 responses to IgG, F(ab')2, and Fab botulinum antitoxins in mice." IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. vol. 25, no. 3, August 2003 (2003-08), pages 397-408, XP009037543 ISSN: 0892-3973 the whole document

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

CO

 \mathbf{v}_{λ}

¥ L

INTERNATIONAL SEARCH REPORT

International application No. PCT/GB2004/002351

ox II Observations where certain cla	aims were found unsearchable (Continuation of item 2 of first sheet)
is International Search Report has not been	established in respect of certain claims under Article 17(2)(2) for the following reasons:
Claims Nos.: 22 because they relate to subject matter	r not required to be searched by this Authority, namely:
Although claim 21 is obody, the search has becompound/composition.	directed to a method of treatment of the human/animal been carried out and based on the alleged effects of the
an extent that no meaningful Internat	itemational Application that do not comply with the prescribed requirements to such tional Search can be carried out, specifically:
see FURTHER INFORMATIO	ON sheet PCT/ISA/210
Claims Nos.: because they are dependent claims	and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
ox III Observations where unity of it	nvention is lacking (Continuation of item 8 of first sheet)
his International Searching Authority found r	multiple inventions in this International application, as follows:
	·
. As all required additional ecarch fee searchable daims.	es were timely paid by the applicant, this International Search Report covers all
As all searchable claims could be se of any additional fee.	earched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.	earched without effort justifying an additional fee, this Authority did not invite payment onal search fees were timely paid by the applicant, this International Search Report fees were paid, specifically claims Nos.:
of any additional fee.	onal search fees were timely paid by the applicant, this International Search Report
As only some of the required additional for which f	onal search fees were timely paid by the applicant, this International Search Report
As only some of the required additional for which f	onal search fees were timely paid by the applicant, this International Search Report fees were paid, specifically claims Nos.:

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Fax:0117932930

Continuation of Box II.2

Claims Nos.: · 22

The application contains two claims numbered as claim 21. For the sake of clarity second claim 21 is referred to as claim 22. Claim 22 does not state any (essential) technical feature of an invention, thus, it is considered to lack clarity in the sense of Art. 6, PCT to such an extent, that it was not searched.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

STAWAILABIE

151